TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice
- PMID: 39139402
- PMCID: PMC11321305
- DOI: 10.1016/j.isci.2024.110520
TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice
Abstract
A tissue resident-like phenotype in tumor infiltrating T cells can limit systemic anti-tumor immunity. Enhanced systemic anti-tumor immunity is observed in head and neck cancer patients after neoadjuvant PD-L1 immune checkpoint blockade (ICB) and transforming growth factor β (TGF-β) neutralization. Using T cell receptor (TCR) sequencing and functional immunity assays in a syngeneic model of oral cancer, we dissect the relative contribution of these treatments to enhanced systemic immunity. The addition of TGF-β neutralization to ICB resulted in the egress of expanded and exhausted CD8+ tumor infiltrating lymphocytes (TILs) into circulation and greater systemic anti-tumor immunity. This enhanced egress associated with reduced expression of Itgae (CD103) and its upstream regulator Znf683. Circulating CD8+ T cells expressed higher Cxcr3 after treatment, an observation also made in samples from patients treated with dual TGF-β neutralization and ICB. These findings provide the scientific rationale for the use of PD-L1 ICB and TGF-β neutralization in newly diagnosed patients with carcinomas prior to definitive treatment of locoregional disease.
Keywords: Biological sciences; Cancer; Cancer systems biology; Immune response; Immunology; Natural sciences; Systems biology.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer.Cancer Cell. 2023 May 8;41(5):887-902.e5. doi: 10.1016/j.ccell.2023.03.014. Epub 2023 Apr 13. Cancer Cell. 2023. PMID: 37059104 Free PMC article.
-
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. Sci Immunol. 2023. PMID: 37683037 Free PMC article.
-
The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018. Front Immunol. 2018. PMID: 30158938 Free PMC article. Review.
-
Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.Carcinogenesis. 2021 Feb 11;42(1):38-47. doi: 10.1093/carcin/bgaa092. Carcinogenesis. 2021. PMID: 32832992
-
Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer.Curr Opin Oncol. 2024 May 1;36(3):136-142. doi: 10.1097/CCO.0000000000001023. Epub 2024 Feb 7. Curr Opin Oncol. 2024. PMID: 38573202 Review.
References
-
- Christo S.N., Evrard M., Park S.L., Gandolfo L.C., Burn T.N., Fonseca R., Newman D.M., Alexandre Y.O., Collins N., Zamudio N.M., et al. Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity. Nat. Immunol. 2021;22:1140–1151. doi: 10.1038/s41590-021-01004-1. - DOI - PubMed
-
- Duhen T., Duhen R., Montler R., Moses J., Moudgil T., de Miranda N.F., Goodall C.P., Blair T.C., Fox B.A., McDermott J.E., et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 2018;9:2724. doi: 10.1038/s41467-018-05072-0. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials